Understanding these endotypes is essential for advancing precision medicine, as it enables the development of targeted therapies, such as biologic therapies that inhibit specific cytokines (e.g., anti-IL-5, anti-IgE) for T2-high asthma, while highlighting the need for novel treatments for T2-low subtypes. Here, IGHE is linked to asthma.